Immuron (IMRN) AI Stock Analysis

• Market Cap: $15.05M
• Dividend Yield: N/A
• Average Volume (3M): 40.37K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.26
• Revenue Growth: 47.17%
• EPS Growth: 26.84%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 6,705,499
• 10 Day Avg. Volume: 31,522
• 30 Day Avg. Volume: 40,373
• PEG Ratio: 0.11
• Price to Book (P/B): 1.89
• Price to Sales (P/S): 2.09
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: 0.42
• Enterprise Value/Revenue: 0.86
• Enterprise Value/Gross Profit: 1.32
• Enterprise Value/Ebitda: -1.17
• 1Y Price Target: $1.50
• Price Target Upside: -21.47% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: $2.00 ▲(4.71% Upside)

Immuron's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. The technical analysis provides some positive momentum, but valuation remains a concern with a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Immuron Business Overview & Revenue Model

Company Description

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.

How the Company Makes Money

Immuron generates revenue primarily through the sale of its products, notably Travelan, which is marketed to consumers as a preventative measure against gastrointestinal infections while traveling. The company also engages in research and development collaborations and licensing agreements that can provide additional revenue streams through upfront payments, milestone payments, and royalties from the commercialization of its products. Partnerships with other pharmaceutical companies and research institutions can enhance its R&D capabilities, potentially leading to new product developments that can contribute to future earnings.

Immuron Financial Statement Overview

Summary

Immuron shows strong revenue growth of 171.7%, but faces significant profitability challenges with a negative net profit margin of -141.5%. Despite a strong gross profit margin of 68.1% and a solid equity position with minimal debt, negative cash flow performance indicates liquidity concerns and the need for external financing.

Income Statement

The company has shown a significant increase in revenue over the past year, with a revenue growth rate of 171.7%. However, profitability remains a challenge as evidenced by the negative net profit margin of -141.5% and consistently negative EBIT and EBITDA margins. The gross profit margin is relatively strong at 68.1%, indicating good control over direct costs, but overall profitability is heavily impacted by high operating expenses.

Balance Sheet

The balance sheet exhibits financial stability with a low debt-to-equity ratio of 0.01, suggesting minimal leverage. However, the return on equity is negative at -54.6%, reflecting the company's struggle to generate profits from shareholder investments. The equity ratio stands at 81.7%, indicating a strong equity position relative to total assets, which provides some financial resilience.

Cash Flow

Cash flow performance is weak, with a negative operating cash flow to net income ratio, indicating that the company is not generating enough cash from operations to cover its net income loss. Free cash flow is also negative, and the free cash flow growth rate is -113.7%, showing a declining trend in cash available after capital expenditures.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.29M	7.29M	4.90M	1.80M	765.19K	145.78K
Gross Profit	4.77M	4.77M	3.34M	1.31M	523.50K	94.70K
EBITDA	-5.39M	-5.31M	-6.88M	-3.36M	-3.08M	-8.33M
Net Income	-5.25M	-5.22M	-6.94M	-3.79M	-2.85M	-8.38M
Balance Sheet
Total Assets	10.09M	10.13M	15.55M	21.99M	24.86M	27.05M
Cash, Cash Equivalents and Short-Term Investments	2.83M	5.87M	11.66M	18.99M	22.11M	25.05M
Total Debt	117.13K	117.13K	173.50K	189.09K	209.79K	20.50K
Total Liabilities	2.06M	2.06M	2.84M	2.37M	1.68M	1.16M
Stockholders Equity	8.03M	8.07M	12.71M	19.62M	23.18M	25.90M
Cash Flow
Free Cash Flow	-6.14M	-6.14M	-5.88M	-2.50M	-3.14M	-4.09M
Operating Cash Flow	-6.14M	-6.14M	-5.88M	-2.49M	-3.13M	-4.08M
Investing Cash Flow	-2.90M	-2.90M	327.56K	-2.74M	11.74K	2.57K
Financing Cash Flow	199.75K	199.75K	829.00	-35.02K	-36.26K	26.49M

Immuron Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRN, the sentiment is Positive. The current price of 1.91 is above the 20-day moving average (MA) of 1.90, above the 50-day MA of 1.80, and above the 200-day MA of 1.85, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 66.26 is Neutral, neither overbought nor oversold. The STOCH value of 73.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMRN.

Immuron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATON	48 Neutral	$13.56M	-0.09	―	―	―	―
IMRN	48 Neutral	$15.05M	―	-49.00%	―	47.17%	26.84%
RLMD	41 Neutral	$71.69M	-1.20	―	―	―	23.17%
HOOK	40 Underperform	$11.04M	-0.16	-84.94%	―	-82.54%	-12.53%
CTXR	38 Underperform	$23.31M	-0.27	―	―	―	18.73%
BTAI	37 Underperform	$51.87M	-0.21	―	―	-63.88%	77.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Immuron Corporate Events

Immuron Limited Secures Auditor Consent for Financial Filings

On September 30, 2025, Immuron Limited announced the consent of Grant Thornton Audit Pty Ltd, its independent registered accounting firm, to incorporate their audit report into the company’s registration statement on Form F-3. This consent facilitates the inclusion of Immuron’s financial statements, dated June 30, 2025, into future filings, potentially impacting investor relations and compliance with regulatory requirements.

Immuron Limited Releases Corporate Governance Statement

On September 25, 2025, Immuron Limited announced the publication of its Appendix 4G and Corporate Governance Statement to the Australian Securities Exchange. This announcement highlights the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, reflecting its commitment to transparency and accountability. The release may impact stakeholders by reinforcing confidence in Immuron’s governance practices and potentially influencing investor perceptions positively.

Immuron Limited Reports FY25 Financial Results with Increased Revenue

On September 2, 2025, Immuron Limited announced its financial results for the fiscal year ending June 30, 2025. The company reported a 48.6% increase in revenue from ordinary activities, reaching $7.29 million, driven by increased sales of Travelan® in Australia and North America. Despite the revenue growth, the company incurred a net loss of $5.25 million, a reduction from the previous year’s loss of $6.94 million, attributed to reduced research and development expenses. The company’s cash position decreased significantly to $2.83 million from $11.66 million the previous year, partly due to the maturation of a fixed-term deposit.

Immuron CEO to Present at Emerging Growth Conference

On August 13, 2025, Immuron Limited announced that its CEO, Steven Lydeamore, will present at the Emerging Growth Conference on August 20, 2025. This presentation is part of Immuron’s efforts to engage with stakeholders and highlight its advancements in biopharmaceuticals, particularly its focus on infectious diseases. The announcement may impact the company’s visibility and stakeholder engagement, potentially influencing its market positioning.